FYN and Alzheimer disease: Masitinib, a tyrosine kinase inhibitor selective for c-Kit, platelet-derived growth factor, Lyn, and to a lesser degree Fyn, was recently used in a 24-week, Phase II dose-ranging trial in France, involving 34 patients with mild-to-moderate AD [45].